


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">31198855</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2391-5463</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>14</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Open medicine (Warsaw, Poland)</Title>
                <ISOAbbreviation>Open Med (Wars)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Propofol Versus 4-hydroxybutyric Acid in Pediatric Cardiac Catheterizations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>416-425</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1515/med-2019-0044</ELocationID>
            <Abstract>
                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Pediatric patients require deep sedation at least for cardiac catheterizations (CCs). Usually, we perform these CCs applying propofol, but we have seen several side effects of this sedative. We have had good experience with 4-hydroxybutyric acid for other sedations. To optimize our standardized CC procedure, we initiated a prospective, randomized trial to compare the two substances.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We analyzed our sedation protocols of all CCs within a period of 12 months. In addition to the primary endpoints, the feasibility of the CCs and the occurrence of severe complications, several other parameters were included in the analysis (vital parameters, blood gas analysis, intervention measures). The protocols were blinded for the first part of the evaluation.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">During the 12-month-period, 36 patients were included in each group. The propofol group showed lower blood pressure values towards the end of the sedations, while the blood gas analyses revealed lower pH levels and higher pCO2 values. The complication rate was low in both groups.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Both procedures are suited for the safe performance of deep sedations for CCs. The application of 4-hydroxybutyric acid seems to have a few advantages with regard to spontaneous breathing, gas exchange, stability of cardiocirculatory parameters and sedation quality.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sauer</LastName>
                    <ForeName>Harald</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic for Pediatric Cardiology, University Hospital of Saarland, Kirrberger Strasse, 66421 Homburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gruenzinger</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic for Dermatology - Lippe Hospital Detmold, Roentgenstrasse 18, 32756 Detmold, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pfeifer</LastName>
                    <ForeName>Jochen</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic for Pediatric Cardiology - University Hospital of Saarland, Kirrberger Strasse, 66421 Homburg (Saar), Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graeber</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Biometry, Epidemiology and Medical Computer Science - University Hospital of Saarland, Kirrberger Strasse, 66421 Homburg (Saar), Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abdul-Khaliq</LastName>
                    <ForeName>Hashim</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic for Pediatric Cardiology - University Hospital of Saarland, Kirrberger Strasse, 66421 Homburg (Saar), Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Open Med (Wars)</MedlineTA>
            <NlmUniqueID>101672167</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">4-hydroxybutyric acid</Keyword>
            <Keyword MajorTopicYN="N">Cardiac catheter</Keyword>
            <Keyword MajorTopicYN="N">Deep sedation</Keyword>
            <Keyword MajorTopicYN="N">Pediatric patients</Keyword>
            <Keyword MajorTopicYN="N">Propofol</Keyword>
        </KeywordList>
        <CoiStatement>Conflict of interest: The corresponding author and the co-authors declare that there is no conflict of interests whatsoever. In particular, there are no contacts with or financial contributions from pharmaceutical companies that produce one or more of the active substances mentioned in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31198855</ArticleId>
            <ArticleId IdType="doi">10.1515/med-2019-0044</ArticleId>
            <ArticleId IdType="pii">med-2019-0044</ArticleId>
            <ArticleId IdType="pmc">PMC6555241</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

